Gaush Meditech Ltd.

As of December 31, 2025, Gaush Meditech Ltd. carries a market capitalization of 1.22B, placing it among publicly traded companies globally. Its enterprise value stands at 1.31B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Gaush Meditech Ltd.'s next confirmed earnings release is scheduled for April 1, 2027.

As of December 31, 2025, Gaush Meditech Ltd. has 147.89M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Gaush Meditech Ltd. maintains a current ratio of 2.40, meaning it holds 2.4x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 22, 2026, Gaush Meditech Ltd.'s stock has declined approximately 55.96% over the past 52 weeks. The 50-day moving average sits at 4.51, while the 200-day moving average is 5.56.

As of December 31, 2025, Gaush Meditech Ltd. holds 487.06M in cash and equivalents against 564.40M in total debt, resulting in a net debt position of 14.09M. Total book value stands at 1.88B, with working capital of 701.60M providing operational flexibility.